CLARIVATE PLC — Form 8-K
Filed July 29, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 52/100
What the filing says
Clarivate reported Q2 2026 revenues of $587.3M (down 5.5% YoY from $621.4M), driven by inorganic disposals and 1.5% organic revenue decline. Net loss was $268.6M (vs. $72.0M loss in Q2 2025), entirely due to a non-cash $221.7M goodwill impairment related to the Life Sciences & Healthcare segment divestiture. The company announced a definitive agreement to sell the LS&H segment to Altaris LLC at ~10x Adjusted EBITDA less capex (~$500M in net proceeds expected); debt was reduced $218.4M in H1 2026 through $211M repayment and opportunistic repurchases at ~6% discount. Management reaffirmed full-year 2026 guidance with no change to outlook.
Why this rating
LS&H divestiture (~$500M proceeds, 15-16% of company market cap) is material but largely pre-announced. Non-cash impairment is accounting charge, not operational loss. Organic decline modest (1.5%). Debt paydown positive; portfolio rationalization strategically sound but modest execution risk. Guidance reaffirmed signals stability.
See more from July 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.